Vicore Pharma Holding AB provides a new interim analysis of the ongoing AIR trial, a phase 2a study in idiopathic pulmonary fibrosis (IPF). The AIR trial is a multi-center open label single arm 24-week trial with the addition of a 12-week extension study evaluating the safety and efficacy of the AT2R agonist (ATRAG) C21 in patients with IPF. After an interim analysis of 41 patients, the previously reported strong effect on lung function is reinforced still without safety concerns, suggesting a strong benefit-risk profile.

The new dataset shows a stabilization of lung capacity already at week 6 and, as already seen in the previous interim analysis, a subsequent increase of forced vital capacity from week 18 to 36. The increase was more pronounced in IPF patients without end-stage destruction of lung parenchyma as documented by high resolution computer tomography.